About Mitochondrial 2-oxoglutarate/malate carrier protein
Mitochondrial 2-oxoglutarate/malate carrier protein (SLC25A11) is a protein
from Homo sapiens identified by UniProt accession
Q02978, 314 residues long.
MolForge cross-references it against 0 known binders and
38 disease associations.
Target properties
| Protein name | Mitochondrial 2-oxoglutarate/malate carrier protein |
|---|
| UniProt accession | Q02978 |
|---|
| Gene | SLC25A11 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 314 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (38)
Diseases linked to this target (Open Targets).
- Paraganglioma · score 0.67
- hereditary pheochromocytoma-paraganglioma · score 0.37
- platelet component distribution width · score 0.17
- platelet count · score 0.16
- mean platelet volume · score 0.15
- platelet crit · score 0.12
- blood protein measurement · score 0.11
- calcium measurement · score 0.10
- endometrial cancer · score 0.09
- hepatocellular carcinoma · score 0.08
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q02978-F1 | alphafold | PREDICTED | 86.75 | — |
Amino-acid sequence (314 residues)
MAATASAGAG GIDGKPRTSP KSVKFLFGGL AGMGATVFVQ PLDLVKNRMQ LSGEGAKTRE YKTSFHALTS ILKAEGLRGI YTGLSAGLLR QATYTTTRLG IYTVLFERLT GADGTPPGFL LKAVIGMTAG ATGAFVGTPA EVALIRMTAD GRLPADQRRG YKNVFNALIR ITREEGVLTL WRGCIPTMAR AVVVNAAQLA SYSQSKQFLL DSGYFSDNIL CHFCASMISG LVTTAASMPV DIAKTRIQNM RMIDGKPEYK NGLDVLFKVV RYEGFFSLWK GFTPYYARLG PHTVLTFIFL EQMNKAYKRL FLSG
Explore Mitochondrial 2-oxoglutarate/malate carrier protein with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets